Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Lung Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
80 drugs · 288 active trials
21 drugs · 605 active trials
51 drugs · 1,369 active trials
Outside the funnel: Phase not stated 2 · Withdrawn 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab | Approved | Phase 4 | 209 | 103 | 113 | 460 | 6 | US | Sep 4, 2014 | Apr 26, 2013 |
| Pemetrexed | Approved | Phase 4 | 174 | 84 | 163 | 550 | 33 | US | Feb 4, 2004 | 2001-08 |
| Paclitaxel | Approved | Phase 4 | 104 | 46 | 128 | 466 | 3 | US | Jan 7, 2005 | 1994-10 |
| Osimertinib | Approved | Phase 4 | 95 | 41 | 26 | 165 | 6 | EU, US | Nov 13, 2015 | Mar 4, 2013 |
| Durvalumab | Approved | Phase 4 | 92 | 32 | 38 | 197 | 4 | US | May 1, 2017 | Oct 25, 2013 |
| Docetaxel | Approved | Phase 4 | 79 | 36 | 117 | 401 | 8 | US | May 14, 1996 | 1996-12 |
| Nivolumab | Approved | Phase 4 | 73 | 29 | 32 | 218 | 6 | EU, US | Dec 22, 2014 | 2006-08 |
| Atezolizumab | Approved | Phase 4 | 67 | 33 | 32 | 164 | 7 | US | May 18, 2016 | Aug 6, 2013 |
| Etoposide | Approved | Phase 4 | 58 | 25 | 51 | 219 | 3 | US | Dec 30, 1986 | 1993-01 |
| Gemcitabine | Approved | Phase 4 | 38 | 19 | 71 | 279 | 3 | US | Aug 4, 2011 | 1997-04 |
| Bevacizumab | Approved | Phase 4 | 38 | 22 | 39 | 227 | 1 | US | Feb 26, 2004 | 2001-11 |
| Cemiplimab | Approved | Phase 3 | 37 | 21 | 8 | 50 | 2 | US | Sep 28, 2018 | May 29, 2017 |
| Ipilimumab | Approved | Phase 3 | 24 | 7 | 13 | 78 | 2 | US | Mar 25, 2011 | 2002-03 |
| Topotecan | Approved | Phase 4 | 23 | 11 | 28 | 92 | 3 | US | May 28, 1996 | 1993-09 |
| Amivantamab | Approved | Phase 3 | 21 | 7 | 4 | 24 | 5 | EU, US | May 21, 2021 | May 24, 2016 |
| Datopotamab Deruxtecan | Approved | Phase 3 | 21 | 8 | 9 | 23 | 1 | US | Jan 17, 2025 | Jan 31, 2018 |
| Lurbinectedin | Approved | Phase 3 | 20 | 13 | 8 | 27 | 3 | EU, US | Jun 15, 2020 | Sep 11, 2013 |
| Tarlatamab | Approved | Phase 3 | 20 | 9 | 6 | 22 | 2 | EU, US | May 16, 2024 | Dec 26, 2017 |
| Ramucirumab | Approved | Phase 3 | 18 | 7 | 6 | 37 | 2 | US | Apr 21, 2014 | 2009-01 |
| Aumolertinib | Approved | Phase 3 | 13 | 5 | 13 | 36 | 1 | EU | Feb 12, 2026 | May 8, 2017 |
| Lorlatinib | Approved | Phase 4 | 13 | 3 | 2 | 23 | 1 | EU | May 6, 2019 | Jan 8, 2014 |
| Lazertinib | Approved | Phase 3 | 12 | 3 | 4 | 21 | 2 | EU, US | Aug 19, 2024 | May 24, 2016 |
| Alectinib | Approved | Phase 4 | 11 | 5 | 6 | 25 | 2 | EU, US | Dec 11, 2015 | Jun 20, 2013 |
| Adagrasib | Approved | Phase 3 | 11 | 6 | 4 | 17 | 2 | EU, US | Dec 12, 2022 | Dec 2, 2020 |
| Sotorasib | Approved | Phase 3 | 10 | 5 | 2 | 22 | 2 | EU, US | May 28, 2021 | Mar 23, 2021 |
| Vinorelbine | Approved | Phase 4 | 9 | 5 | 32 | 92 | 1 | US | Jul 22, 2009 | 1995-02 |
| Trametinib | Approved | Phase 4 | 8 | 2 | 1 | 26 | 2 | US | May 29, 2013 | 2011-09 |
| Erlotinib | Approved | Phase 4 | 6 | 1 | 38 | 211 | 4 | US | Aug 28, 2015 | 2004-04 |
| Selpercatinib | Approved | Phase 4 | 6 | 0 | 2 | 8 | 2 | US | May 8, 2020 | May 2, 2017 |
| Gefitinib | Approved | Phase 4 | 5 | 0 | 38 | 124 | 3 | EU, US | Jun 24, 2009 | 1999-09 |
| Tepotinib | Approved | Phase 3 | 5 | 3 | 1 | 9 | 2 | EU, US | Feb 3, 2021 | Dec 23, 2013 |
| Entrectinib | Approved | Phase 3 | 5 | 1 | 3 | 6 | 3 | EU, US | Aug 15, 2019 | Nov 19, 2015 |
| Afatinib | Approved | Phase 4 | 4 | 1 | 11 | 50 | 3 | EU, US | Jul 12, 2013 | 2007-08 |
| Binimetinib | Approved | Phase 2 | 4 | 0 | 0 | 17 | 1 | US | Jun 27, 2018 | Dec 30, 2013 |
| Pralsetinib | Approved | Phase 4 | 4 | 3 | 1 | 7 | 2 | EU, US | Sep 4, 2020 | Mar 17, 2017 |
| Taletrectinib | Approved | Phase 3 | 4 | 2 | 2 | 4 | 1 | US | Jun 11, 2025 | Jul 7, 2020 |
| Zongertinib | Approved | Phase 3 | 4 | 2 | 2 | 4 | 1 | US | Aug 8, 2025 | Jul 2, 2021 |
| Erlotinib Hydrochloride | Approved | Phase 3 | 3 | 0 | 10 | 65 | 2 | US | Nov 5, 2019 | 2001-12 |
| Capmatinib | Approved | Phase 4 | 3 | 1 | 2 | 21 | 2 | EU, US | May 6, 2020 | Apr 5, 2012 |
| Dabrafenib | Approved | Phase 4 | 3 | 2 | 1 | 5 | 2 | US | May 29, 2013 | Aug 17, 2015 |
| Osimertinib Mesylate | Approved | Phase 3 | 3 | 2 | 1 | 5 | 5 | US | Nov 13, 2015 | Aug 6, 2021 |
| Repotrectinib | Approved | Phase 3 | 3 | 2 | 1 | 4 | 2 | EU, US | Nov 15, 2023 | Feb 11, 2022 |
| Sugemalimab | Approved | Phase 3 | 3 | 3 | 2 | 4 | 1 | EU | Jul 24, 2024 | Jan 12, 2021 |
| Encorafenib | Approved | Phase 2 | 2 | 0 | 0 | 6 | 1 | US | Jun 27, 2018 | 2015-06 |
| Trastuzumab Deruxtecan | Approved | Phase 2 | 2 | 1 | 0 | 2 | 1 | US | Dec 20, 2019 | Nov 12, 2020 |
| Nintedanib | Approved | Phase 3 | 1 | 0 | 2 | 20 | 1 | EU | Nov 21, 2014 | 2005-06 |
| Sevabertinib | Approved | Phase 3 | 1 | 1 | 1 | 6 | 1 | US | Nov 19, 2025 | Jan 25, 2024 |
| Porfimer | Approved | Phase 2 | 0 | 0 | 0 | 8 | 1 | US | Dec 27, 1995 | 2004-11 |
| Dacomitinib | Approved | Phase 3 | 0 | 0 | 1 | 7 | 1 | US | Sep 27, 2018 | Feb 5, 2008 |
| Dacomitinib | Approved | — | 0 | 0 | 0 | 0 | 1 | US | Sep 27, 2018 | — |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.